Wall Street analysts predict that Cytokinetics, Inc. (NASDAQ:CYTK) will post earnings of ($0.55) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Cytokinetics’ earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.58). Cytokinetics reported earnings of ($0.75) per share in the same quarter last year, which would indicate a positive year over year growth rate of 26.7%. The firm is scheduled to report its next quarterly earnings results on Thursday, February 21st.

On average, analysts expect that Cytokinetics will report full-year earnings of ($1.96) per share for the current fiscal year, with EPS estimates ranging from ($2.05) to ($1.87). For the next financial year, analysts forecast that the company will post earnings of ($1.72) per share, with EPS estimates ranging from ($2.14) to ($1.37). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that cover Cytokinetics.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.11. The company had revenue of $10.64 million for the quarter, compared to the consensus estimate of $2.23 million.

Several brokerages have issued reports on CYTK. BidaskClub raised Cytokinetics from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 28th. Zacks Investment Research cut Cytokinetics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 26th. ValuEngine raised Cytokinetics from a “hold” rating to a “buy” rating in a research report on Wednesday, October 3rd. Morgan Stanley set a $10.00 price objective on Cytokinetics and gave the stock a “hold” rating in a research report on Friday, October 5th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price objective on shares of Cytokinetics in a research report on Wednesday, October 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. Cytokinetics presently has a consensus rating of “Buy” and an average price target of $12.75.

In related news, CEO Robert I. Blum sold 4,000 shares of Cytokinetics stock in a transaction dated Friday, October 5th. The stock was sold at an average price of $8.79, for a total value of $35,160.00. Following the completion of the transaction, the chief executive officer now owns 160,022 shares in the company, valued at approximately $1,406,593.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 16,500 shares of company stock valued at $131,090 in the last quarter. Company insiders own 5.10% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its stake in shares of Cytokinetics by 233.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 229,377 shares of the biopharmaceutical company’s stock valued at $2,259,000 after purchasing an additional 160,622 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Cytokinetics in the 3rd quarter valued at about $111,000. FMR LLC increased its stake in shares of Cytokinetics by 3.7% in the 3rd quarter. FMR LLC now owns 1,956,383 shares of the biopharmaceutical company’s stock valued at $19,271,000 after purchasing an additional 70,631 shares in the last quarter. BlackRock Inc. increased its stake in shares of Cytokinetics by 9.5% in the 3rd quarter. BlackRock Inc. now owns 8,698,387 shares of the biopharmaceutical company’s stock valued at $85,680,000 after purchasing an additional 754,593 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Cytokinetics by 5.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 581,465 shares of the biopharmaceutical company’s stock valued at $5,727,000 after purchasing an additional 29,923 shares in the last quarter. Hedge funds and other institutional investors own 68.25% of the company’s stock.

NASDAQ CYTK traded down $0.12 during midday trading on Tuesday, hitting $6.50. 286,900 shares of the company traded hands, compared to its average volume of 345,277. The company has a current ratio of 10.57, a quick ratio of 8.95 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $388.95 million, a PE ratio of -2.51 and a beta of 1.98. Cytokinetics has a 52 week low of $6.20 and a 52 week high of $12.00.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Featured Story: Market Capitalization and Individual Investors

Get a free copy of the Zacks research report on Cytokinetics (CYTK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.